Table 1 Demographic, clinical data, HGS, muscle mass metrics and sarcopenia prevalence rates in AD patients and controls

    Male/Female

61/84

20/31

0.13

0.722

    Age, y

71.51 ± 8.31

64.71 ± 11.02

4.60

<0.0001

    BMI

25.88 ± 3.96

27.65 ± 4.75

−2.61

<0.01

    MMSE

16.92 ± 5.39

27.51 ± 1.89

−13.72

<0.0001

    HGS

17.47 ± 7.22

21.78 ± 8.30

13.93^a

<0.0005

    SMI

9.73 ± 1.59

9.98 ± 1.75

0.01^a

0.938

    SM

26.38 ± 5.31

25.75 ± 6.27

0.17^a

0.683

    ASM

20.85 ± 4.08

19.88 ± 4.10

0.07^a

0.790

    ASM/height²

7.54 ± 0.97

7.88 ± 1.28

0.00^a

0.956

    MQI

0.70 ± 0.29

0.84 ± 0.28

11.33^a

<0.001

    EWGSOP1, Low muscle mass (%)

37 (25.5%)

9 (17.6%)

1.30

0.254

    EWGSOP1, Low muscle strength (%)

119 (82.1%)

29 (56.9%)

12.96

<0.0005

    EWGSOP1, Sarcopenia (%)

34 (23.4%)

6 (11.8%)

3.17

0.075

    EWGSOP2, Low muscle strength (%)

95 (65.5%)

18 (35.3%)

14.12

<0.0005

    EWGSOP2, Low muscle mass (%)

6 (4.1%)

3 (5.9%)

0.26

0.609

    EWGSOP2, Sarcopenia (%)

5 (3.4%)

1 (2.0%)

0.28

0.596

    FNIH, Low muscle strength (%)

91 (62.8%)

18 (35.3%)

11.53

<0.001

    FNIH, Low muscle mass (%)

18 (12.4%)

10 (19.6%)

1.59

0.207

    FNIH, Sarcopenia (%)

14 (9.7%)

3 (5.9%)

0.68

0.410